Earnings summaries and quarterly performance for Harvard Apparatus Regenerative Technology.
Executive leadership at Harvard Apparatus Regenerative Technology.
Board of directors at Harvard Apparatus Regenerative Technology.
Research analysts covering Harvard Apparatus Regenerative Technology.
Recent press releases and 8-K filings for HRGN.
Harvard Apparatus Regenerative Technology, Inc. Announces Private Placement and Board Changes
HRGN
Board Change
Proxy Vote Outcomes
- Harvard Apparatus Regenerative Technology, Inc. entered into Securities Purchase Agreements, effective December 30, 2025, for a private placement with certain investors.
- The company sold 411,765 shares of common stock for an aggregate purchase price of approximately $0.7 million, at a price of $1.70 per share.
- The Board of Directors will be increased to eight (8) members, with a new individual being added as a Board Designee.
- The company will seek stockholder approval to amend its Charter to eliminate classified directors and allow stockholders owning at least 35% of voting power to call special meetings.
Jan 6, 2026, 3:06 PM
HRGN Reports Q3 2025 Results and Provides Q4 2025 Outlook
HRGN
Earnings
Guidance Update
Debt Issuance
- HRGN reported Q3 2025 revenue of $20.6 million and a gross margin of 58.4%, exceeding its guidance range.
- The company's Adjusted EBITDA for Q3 2025 was $2.0 million, and it generated $6.8 million in cash from operations year-to-date, a significant improvement from the prior year.
- For Q4 2025, HRGN expects revenues between $22.5 million and $24.5 million and a gross margin of 58-60%.
- HRGN is actively working to refinance or repay its existing credit agreement in Q4 2025 to strengthen its capital structure, supported by strong demand and the highest backlog in nearly two years.
Nov 10, 2025, 9:00 PM
Quarterly earnings call transcripts for Harvard Apparatus Regenerative Technology.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more